Adding Choline to Iron Treatment to Improve Memory and Learning in Infants with Iron Deficiency Anemia
A Randomized, Double-Blind Study in Uganda
Led by University of Minnesota · Updated on 2026-08-05
300
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effect of choline supplementation alongside iron therapy in infants with iron deficiency anemia. The study focuses on infants around 6 months old, investigating whether adding daily choline supplements for nine months can improve brain development and memory, particularly in the hippocampus, compared to iron therapy with a placebo. Iron deficiency affects many children worldwide and early treatment often does not fully reverse brain dysfunction, so this study explores a potential low-cost nutritional addition to standard care.
Participants will be randomly assigned to one of two groups one receiving daily iron plus 200 mg of choline bitartrate supplements, and the other receiving iron plus a daily identical placebo. The supplementation lasts for nine months. This double-blinded trial will compare neurobehavioral outcomes between the two groups to see if choline improves recognition memory and overall brain function.
During the study, infants will be assessed using tests like the Elicited Imitation score, Mullen Scales of Early Learning, Behavior Rating Scale composite score, and Early Childhood Vigilance Test at nine months after enrollment. These evaluations measure memory, learning, attention, and behavior. The study will monitor safety and development throughout the trial period, which runs until September 2027, involving regular visits to support adherence and data collection.
CONDITIONS
Brief Title
Choline and Iron Deficiency
Research Team
S
Sarah Cusick
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Choline supplementation
Placebo
Standard oral iron
What this is
Daily choline bitartrate supplementation (200 mg per day) given for 9 months to infants with iron deficiency anemia
Daily identical placebo given for 9 months to closely match the investigational arm
Oral iron supplementation is the current global standard for treating pediatric iron deficiency anemia
Role in the study
Investigational treatment arm testing choline as a supplement alongside standard care (iron deficiency context)
Placebo control arm to compare against choline supplementation
Represents typical treatment to which investigational results will be compared in clinical interpretation
Primary use
Supplement aiming to improve developmental outcomes in infants with iron deficiency anemia beyond standard iron repair
Control condition without active supplementation to isolate choline’s effect
Restore iron levels and support neurodevelopment through iron repletion
Administration
Given once daily as 200 mg choline bitartrate supplement for 9 months
Given once daily as identical inactive supplement for 9 months
Oral iron is given daily or per clinical dosing guidelines
Clinical evidence
Evidence limited to this trial protocol; clinical outcomes not yet reported
No active component; serves as baseline comparator
Well‑established efficacy in restoring iron status and supporting development in children
Important limitations
Long‑term safety and effect on developmental outcomes are not yet known
Does not offer therapeutic benefit and solely serves as control
May cause gastrointestinal discomfort or dosing challenges in young children
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 5Months - 7Months
All Genders
Eligibility Criteria
You may qualify if you...
Age 6 months plus or minus 28 days
Hemoglobin level less than 11.0 g/dL
Zinc protoporphyrin (ZPP) level greater than or equal to 80
Body temperature below 37.5°C
Malaria-negative by Rapid Diagnostic Test
Mother is HIV-negative
You will not qualify if you...
Developmental disorder
Severe malnutrition such as severe wasting or bipedal edema
Known sickle cell disease
Neurologic disorder, brain injury, or other condition affecting brain development
Not currently breastfeeding
Birthweight less than 2000 grams
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 9 months
Participants receive daily iron plus either choline bitartrate or a placebo supplement for nine months.
Regular visits for supplement distribution and assessments
Follow-up
Duration - At 9 months after enrollment
Participants undergo neurobehavioral tests to measure memory, learning, attention, and behavior nine months after enrollment.
1 follow-up visit for assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Study of 129Xe Gas Exchange MRI to Understand Lung and Heart Function in Adults
Improving Primary Care Diagnostic Safety and Efficiency with New Evidence-Based Team Interventions A Stepped Wedge Cluster Randomized Trial
A Phase 2 Multicenter Study Evaluating Luspatercept for Anemia Due to Chronic Kidney Disease
Evaluating Elritercept Compared to Placebo for Anemia in Adults With Myelofibrosis on Ruxolitinib Therapy
Comparing Elritercept and Epoetin Alfa Injections for Treating Anemia in Adults with Lower-Risk Myelodysplastic Syndromes Who Need Regular Blood Transfusions
Phase 1 Study of APG-5918 to Assess Safety, Pharmacokinetics,
and Early Effectiveness in Healthy Adults and Adults with Anemia
Study Evaluating the Safety and Effects of CTX001 on Iron Levels in Healthy Adults Aged 18 to 55
Evaluating Readiness to Expand Antenatal Multiple Micronutrient Supplementation in Cambodia
A Mixed-Methods Study on Health System and Pregnant Women in Takeo Province
Adding Choline to Iron Treatment to Improve Memory and Learning in Infants with Iron Deficiency Anemia
A Randomized, Double-Blind Study in Uganda
Evaluating Delayed Versus Immediate Umbilical Cord Clamping in Preterm Infants Born Between 32 and 37 Weeks
Impact on Early Neonatal Health Outcomes in a Tunisian Maternity Center
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Supplemental choline to prevent and treat learning and memory deficits of early-life iron deficiency (The SupCHO Study): study protocol for a randomized, placebo-controlled trial in Ugandan infants with iron deficiency anemia.